Why Are People Talking About Investing in Astellas Pharma (ALPMF)?

By Tamara Parker • Friday, May 12 15:00 • Permanent Link

Shares of Large-cap healthcare company Astellas Pharma moved 3.8 this afternoon, and are now trading at $15.93 per share. On the other hand, the average analyst target price for the stock is $None.

Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals in the Japan, United States, and internationally.

Astellas Pharma investors should be aware of the below:

Astellas Pharma has moved 1.1% over the last year.

The company has a price to earnings growth (PEG) ratio of 17894.5. A number between 0 and 1 could mean that the market is undervaluing Astellas Pharma's estimated growth potential

Its Price to Book (P/B) ratio is 0.02

Astellas Pharma currently returns an annual dividend yield of 391.0%.

None

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.